Micron Technologies Limited @ InformEx USA 2010, stand 2135

Published: 11-Feb-2010

Micron Technologies Limited @ InformEx USA 2010, stand 2135
Micron Technologies, the leading provider of particle size reduction for pharmaceutical ingredients, will be announcing the achievement of two major steps in the company history; first, the inauguration in a couple of months of a brand new facility in the US, located at Malvern, Pennsylvania, dedicated to the particle size reduction and material characterisation of active pharmaceutical ingredients; this 90,000ft2 state of the art facility designed for cGMP manufacturing will be equipped with several large units for micronisation of commercial volumes including potent compounds.
Second, Micron Technologies has invested in what is believed to be the largest micronisation suite under full containment available in the market; this unit will be ready for customers very soon and has the ability to fully contain small scale as well as large scale equipment to micronise potent and highly potent compounds.
Micronisation is the quickest, most reliable, reproducible and cost-effective technique to bring a poorly soluble drug to market and these investments will enhance Micron Technologies" leadership in particle size reduction and material characterisation.
  • Companies:
  • Catalent
  • Informa
See more

You may also like

Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

Read more
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten

Trending Articles

  1. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end track-and-trace capabilities for regulated industries where audit readiness and patient safety are critical
  2. Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager The Swiss pharma company has agreed to pay $575m upfront for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases
  3. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  4. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  5. Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif

You may also like

Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Manufacturing
Codis acquires Catalent's Nottingham site to become Europe's leading end-to-end spray dry provider

Codis acquires Catalent's Nottingham site to become Europe's leading end-to-end spray dry provider

The deal pairs Nottingham's OSD development and clinical supply expertise with Codis' commercial-scale Haverhill facility, offering pharma partners an integrated ASD development-to-manufacture pathway within a single quality system
Packaging
Pharmapack announces expansion to Asia with new event in Singapore, set for November 2026

Pharmapack announces expansion to Asia with new event in Singapore, set for November 2026

Pharmapack, the leading European platform for pharmaceutical packaging and drug delivery innovation, announces the launch of Pharmapack Asia, coming to Singapore in November 2026
Marketing
CPHI Pharma Awards 2025 winners announced

CPHI Pharma Awards 2025 winners announced

Hundreds of entries received across 13 categories showcasing industry-wide excellence
Pharmaceutical
Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Manufacturing
CPHI & PMEC China sees surge in international attendance as globalpharma trade outlook strengthens

CPHI & PMEC China sees surge in international attendance as globalpharma trade outlook strengthens

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing,as easing tariffs fuel growth
Manufacturing
Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services

Ardena acquires Catalent's US oral dose manufacturing facility, adding further bioanalytical services

The CRO/CDMO will now integrate its advanced late-stage and small-scale commercial oral drug product manufacturing services with an extended list of bioanalytical services, enhancing its offering to clients in the North American region
Subscribe now